Background illustration for clinical trials search

Small Cell Lung Cancer Clinical Trials

Browse 642 small cell lung cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

for
Extensive-stage Small-cell Lung Cancer
Location: Rock Hill SC, Jacksonville FL, Atlanta GA, Lexington KY,
Sponsor: Jazz Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07459634

Phase2, Recruiting

MK-3475A±Calderasib (MK-1084) in Completely Resected Stage IIA-IIIB (N2) KRAS G12Cm NSCLC (MK-1084-013)

for
Non-small Cell Lung Cancer
Location: Moncton, Chicoutimi, Montreal
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07431827

Phase3, Recruiting

First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2)

for
Advanced Non-small Cell Lung Cancer, EGFR Mutation,
Location: Nashville TN
Sponsor: Bayer

Sex: All

Age: 18+

Code: NCT05099172

Phase1, Phase2, Recruiting

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

for
Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC),
Location: Athens GA, Knoxville TN, Huntsville AL, Hinsdale IL,
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07489066

Phase2, Recruiting

A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation

for
Non-small Cell Lung Cancer (NSCLC)
Location: Edison NJ, Arlington VA, Glendale CA, Los Angeles CA,
Sponsor: Astellas Pharma Global Development, Inc.

Sex: All

Age: 18+

Code: NCT07566052

Phase3, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer, Metastatic Lung Cancer
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT07603856

Phase2, Recruiting

A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy

for
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Location: Lexington KY, Houston TX, Seattle WA
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18+

Code: NCT07564401

Phase1, Phase2, Recruiting

A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.

for
Non Small Cell Lung Cancer (Squamous or Non Squamous),
Location: Mineola NY, White Plains NY, The Bronx NY, New York NY,
Sponsor: Eikon Therapeutics

Sex: All

Age: 18+

Code: NCT07365319

Phase2, Phase3, Recruiting

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

for
Advanced Solid Tumor, Non-Small Cell Lung Cancer,
Location: Fairfax VA, Tampa FL, Sarasota FL
Sponsor: Blueprint Medicines Corporation

Sex: All

Age: 18+

Code: NCT07629960

Phase1, Phase2, Recruiting

Phase 2 Study for the Patient, Who Has Diagnosed With Small Cell Lung Cancer (SCLC) or Non Small Cell Lung Cancer (NSCLC) or Renal Cell Carcinoma (RCC) and Finished the First Line Stand Treatment , Need More Treatment

for
Small Cell Lung Cancer, Renal Cell Carcinoma (RCC),
Location: Cleveland OH, Birmingham AL, St Louis MO
Sponsor: Advenchen Pharmaceuticals, LLC.

Sex: All

Age: 18+

Code: NCT05363280

Phase2, Recruiting

A Study of Ivonescimab in People With Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07594522

Phase1, Phase2, Recruiting

Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)

for
Small Cell Lung Cancer
Location: New York NY, Fairfax VA, Tampa FL, Zion IL, Memphis TN,
Sponsor: Amgen

Sex: All

Age: 18 - 70+

Code: NCT07531095

Phase1, Recruiting

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

for
Advanced Non-Small Cell Lung Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07415005

Phase2, Recruiting

A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07535437

Phase1, Phase2, Recruiting

A Study of Ivonescimab, Chemotherapy, and Stereotactic Radiosurgery for People With Non-Small Cell Lung Cancer

for
Non-Small Cell Lung Cancer
Location: Commack NY, Rockville Centre NY, Harrison NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT07535463

Phase1, Phase2, Recruiting

MOnaliZumab in Combination With durvAlumab (MEDI4736) for tRreatmenT of Small Cell Lung Cancer

for
Small Cell Lung Cancer, SCLC,
Location: Charlottesville VA, Detroit MI, Indianapolis IN,
Sponsor: Hirva Mamdani

Sex: All

Age: 18+

Code: NCT05903092

Phase2, Recruiting

Pilot Study of Bone Mineral Density Changes During Anti-PD-1 Immunotherapy

for
Breast Cancer (Triple Negative Breast Cancer (TNBC)),
Location: Nashville TN
Sponsor: Jessica Mezzanotte Sharpe

Sex: All

Age: 18+

Code: NCT07555210

Recruiting

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)

for
Non-Small Cell Lung Cancer
Location: Fairfax VA, Atlanta GA, Santa Monica CA
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07098338

Phase2, Recruiting

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

for
Non-small Cell Lung Cancer (NSCLC)
Location: Halifax, Moncton, South Portland ME, Boston MA,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07291037

Phase3, Recruiting

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

for
Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer,
Location: Tampa FL
Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Sex: All

Age: 18+

Code: NCT05681780

Phase1, Recruiting